The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Open accessAbstract
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust immune responses. Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver. Here, we screened a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model when administered IM. A subset of compounds was selected and further evaluated for tolerability, immunogenicity, and expression in rodents and non-human primates (NHPs). A lead formulation was identified that yielded a robust immune response with improved tolerability. More importantly for vaccines, increased innate immune stimulation driven by LNPs does not equate to increased immunogenicity, illustrating that mRNA vaccine tolerability can be improved without affecting potency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection31 or in muscle cells after intramuscular (i.m.) injection.32”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [32]
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [291]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“For Moderna's LNP formulation, Hassett et al. reported that the SM-102 lipid was selected based on its improved tolerability profile in non-human primates, as evidenced by a reduced local reactogenicity (e.g., edema and erythema) and lowest induction of systemic cytokine responses (e.g., IL-6) [13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Lanciotti, R. S., Kosoy, O. L., Laven, J. J., Velez, J. O., Lambert, A. J., Johnson, A. J., Stanfield, S. M., & Duffy, M. R. (2008) · Emerging infectious diseases · doi:10.3201/eid1408.080287 · Cited by 2,173
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“8.(11,13,23) However, the best lipids with respect to protein expression after IV administration generally had lower pKas than the best lipids for protein expression after IM administration.”
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. F. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 965
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 918
Watts, J. K. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781837671328-00350 · Cited by 6
Why Na+ has higher propensity than K+ to condense DNA in a crowded environment
Kolesnikov, E. S., Gushchin, I., Zhilyaev, P. A., & Onufriev, A. V. (2023) · The Journal of Chemical Physics · doi:10.1063/5.0159341 · Cited by 6
Non‐Viral RNA Delivery During Pregnancy: Opportunities and Challenges
Chaudhary, N., Newby, A. N., & Whitehead, K. A. (2023) · Small · doi:10.1002/smll.202306134 · Cited by 6
Tamming, L. A., Duque, D., Bavananthasivam, J., Tran, A., Lansdell, C., Frahm, G. E., Wu, J., Fekete, E. E. F., Creskey, M., Raman, S. N. T., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101325 · Cited by 6
Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies
Hassan, M., Zalkifal, M., Wahab, A., Afzal, S., Rafique, S., Shahid, M., Khan, M. A., Ahmed, N., Idrees, M., & Shahıd, A. A. (2021) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2021038075 · Cited by 6
Harnessing nucleic acid technologies for human health on earth and in space
Sarli, S. L., & Watts, J. K. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.08.006 · Cited by 6
Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and AtherosclerosisPreprint
Zhou, Z., Zhu, J., Yeh, C., Meliton, A. Y., Wu, D., Huang, R., Shentu, T., Ray, A. G., Wiseman, D., Budina, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.09.632179 · Cited by 6
The rise of mRNA therapeutic vaccines
Du, J., Fan, Z., Huang, J., Li, Z., Hu, H., & Li, Y. (2025) · RSC Pharmaceutics · doi:10.1039/d4pm00309h · Cited by 5
Teffera, Z. H., Abebaw, D., Akelew, Y., Belayneh, M., Mesganaw, B., Selabat, B., Tefera, S., Belew, H., & Gedefaw, L. (2025) · Discover Viruses. · doi:10.1007/s44370-025-00019-8 · Cited by 5
Lipid nanoparticle-assisted mRNA therapy for cancer treatment
Kim, H.-J., Le, N. D., Oh, H.-J., Kim, B., Yoo, E., Kim, J., & Yim, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0247029 · Cited by 5
Sato, M., Samaridou, E., Beck‐Broichsitter, M., Maeki, M., Kita, S., Tokeshi, M., Maenaka, K., Harashima, H., & Sato, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091194 · Cited by 5
Vaquero, A. P., Calderón-Ruiz, P., Gambaro, R. C., Berti, I. R., Limeres, M. A., Ghazi, S. F.-E., Huck‐Iriart, C., Meyer, C. U., Cacicedo, M. L., Hankeln, T., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148058 · Cited by 5
Anindita, J., Tanaka, H., Oyama, R., Matsumaru, A., Nakai, Y., Tange, K., Nagaoka, K., Nakanishi, H., Kawamura, T., Tanaka, T., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114414 · Cited by 5
Recent advances in engineering approaches for delivery of mRNA-based therapeutics
Prinindya, K. N. N., Ashraf, G. M., Uddin, S., Mahdi, E., & Hasan, A. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214667 · Cited by 6
Decoding Undesirable Inflammatory Responses of Nucleic Acid‐Delivering Lipid Nanoparticles
Hu, R., Dou, Y., Li, C., Mu, Y., Ouyang, H., Shen, W., & Zhang, J. (2026) · Advanced Science · doi:10.1002/advs.75548 · Cited by 5
Efficient prime editing in vivo and in vitro using lipid nanoparticles
Jiang, A. Y., Cristian, A., Brooks, D. L., Feierman, E. R., Chen, P., Whittaker, M. N., Pierce, S. E., Sakai, H. A., Chen, H., Liu, D., et al. (2026) · Nature Nanotechnology · doi:10.1038/s41565-026-02200-6 · Cited by 5
He, Z., Le, Z., Shi, Y., Liu, L., Liu, Z., & Chen, Y. (2023) · Angewandte Chemie · doi:10.1002/ange.202310401 · Cited by 5
Development and application of an uncapped mRNA platform
Zheng, X., Liu, B., Ni, P., Cai, L., Shi, X., Ke, Z., Zhang, S., Hu, B., Yang, B., Xu, Y., et al. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2437046 · Cited by 5
Brandys, P., Albariño, C. G., Jain, S., Merenkova, I., Schork, N. J., Deng, A., Valière, M., & Herold, J. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127530 · Cited by 5
Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery
Raza, A., Zhang, R., Lu, R., Wen, J., & Wu, W. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2555507 · Cited by 7
Jefferies, W. A., Choi, K. B., Ribeca, P., Kari, S., Young, J. B., Hui, E., Qi, S. Y., Garrovillas, E., Fan, J., Cho, B. M. Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66252-3 · Cited by 5
Lipid-based nanoparticles and their recent advances
Sujeevan, O. (2024) · GSC Advanced Research and Reviews · doi:10.30574/gscarr.2024.18.3.0096 · Cited by 5
Pallás, R. M. (2024) · Vacunas (English Edition) · doi:10.1016/j.vacune.2024.05.002 · Cited by 5
A statistical-physics approach for codon usage optimisation
Luna-Cerralbo, D., Blasco-Machín, I., Adame-Pérez, S., Lampaya, V., Larraga, A., Alejo, T., Martínez-Oliván, J., Broset, E., & Bruscolini, P. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.07.020 · Cited by 5
Vacunas SARS CoV-2, estudios en fase III
Guelfenbein, C. I., Torres, J. P., & de Pablo, M. E. S. (2021) · Revista chilena de infectología · doi:10.4067/s0716-10182021000100088 · Cited by 8
Advances in mRNA vaccines for viral diseases
Huang, Y., Zhu, X., Guo, X., Zhou, Y., Liu, D., Mao, J., Xiong, Y., Deng, Y., & Gao, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28924 · Cited by 5
Kelly, M. P., Napolitano, T., Anand, P., Ho, J. S. K., Jabeen, S., Kuppan, J. P., Manir, S., & Holford, M. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00494 · Cited by 5
A Historical Overview on mRNA Vaccine Development
Verbeke, R., Cheng, M. H. Y., & Cullis, P. R. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch1 · Cited by 5
Melamed, J. R., Muscat-Rivera, J., Kegel, M., Chaboub, L. S., Perez‐Tremble, R., Bhalla, N. S., Ni, H., Sun, H., & Weissman, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.683125 · Cited by 5
In Vivo Delivery Processes and Development Strategies of Lipid Nanoparticles
Cheng, J., Jian, L., Chen, Z., Li, Z., Yu, Y., & Wu, Y. (2024) · ChemBioChem · doi:10.1002/cbic.202400481 · Cited by 4
A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues
Wu, B., Liu, Y., Zhang, X., Luo, D., Wang, X., Qiao, C., & Liu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420216 · Cited by 4
Seshire, A., Duan, Y., & Lang, K. (2024) · Handbook of experimental pharmacology · doi:10.1007/164_2024_723 · Cited by 4
Ether bond-modified lipid nanoparticles for enhancing the treatment effect of hepatic fibrosis
Chu, R., Kong, J., Gao, Q., Yang, Y., Pan, T., Lu, X., Wang, Z., Wang, Y., & He, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125192 · Cited by 4
Insights from Computational Studies of Polymeric Systems for Nucleic Acid Delivery
Ziebarth, J. D., Shadman, H., & Wang, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00994 · Cited by 4
Yuan, Z., Luozhong, S., Li, R., Gu, W., Chen, Y., Bhashyam, D., Lai, R., & Jiang, S. (2025) · ACS Nano · doi:10.1021/acsnano.5c02001 · Cited by 6
Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms
Pazoki, A., Dadfar, S., Alirezaee, A., Oksenych, V., & Haghmorad, D. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1617352 · Cited by 4
Evaluation of dynamical-billiard-shaped chambers as divergent elements of passive micromixers
Ochoa, A., Olguín, L. F., & Poiré, E. C. (2025) · Microfluidics and Nanofluidics · doi:10.1007/s10404-025-02817-4 · Cited by 4
Eudragit® S 100 Coating of Lipid Nanoparticles for Oral Delivery of RNA
Haque, M. A., Shrestha, A., & Mattheolabakis, G. (2025) · Processes · doi:10.3390/pr13082477 · Cited by 4
Novel Swelling‐Lytic Cell Death Triggered by Cargo‐Free Ionizable Lipid Nanoparticles
Wu, J., Zhao, Z., Wu, H., Lin, S., Huang, L., Chen, G., Yang, Y., Wang, H., Yan, H., Yonghui, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202509208 · Cited by 4
Zhang, Y., Li, X., Li, H., Zhang, R., Zhang, T., Juma, T., Zhou, Y., Guo, Q., Zhao, H., & Cao, Y. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1641236 · Cited by 4
Lokras, A. G., Baghel, S. S., Jensen, R. F., Thakur, A., Franzyk, H., Thofte, O., Herrera‐Barrera, M., Landry, M. R., Ongun, M., Tami, A., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202505627 · Cited by 5
Muscle-targeting LNP vaccines enable potent immune responses against varicella zoster virus
Zhang, H., Ma, J., Jin, L., Ma, Y., Dong, K., Li, J., Yu, F., & Song, G. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01961-2 · Cited by 4
Technical Considerations of Pharmacokinetic Assays for LNP-mRNA Drug Products by RT-qPCR
Pennucci, J. J., Hays, A. L., Adamowicz, W. O., Azadeh, M., Benhammadi, M., Portabella, E. B., Cheng, M., Colletti, K. S., Dholakiya, S. L., Doddareddy, R., et al. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01122-w · Cited by 4
Kunishima, Y., Senpuku, K., Kataoka-Nakamura, C., Hirai, T., & Yoshioka, Y. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102731 · Cited by 4
Wu, Y., Yuanjia, H., Wang, J., & Ouyang, D. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.044 · Cited by 4
Cung, J., Husni, P., & Oh, K. T. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s557784 · Cited by 4
Go, Y. J., Jadamba, E., & Shin, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411960 · Cited by 4
Enhanced‐mRNA Delivery Using Ultrasound‐Delivered Anchors for Bioorthogonal Ligation
Ianni, E. D., Jeon, J., Mohammadi, S., Hu, H., Quintana, J. M., Lee, C., Haidar, E. A., Goemans, M., Zargani‐Piccardi, A., Mahamdeh, M., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202523437 · Cited by 4
Nam, J., Ahn, J., Shin, J., Lee, N., Lee, Y. K., Cho, S. M., Kim, P., Kang, G., Ha, S., & Jung, H. (2026) · Advanced Science · doi:10.1002/advs.202522846 · Cited by 4
Goody, S. M. G., Rowbottom, C., Liu, Y., & Chen, N. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102948 · Cited by 5
Cheng, X., Li, Q., Zu, H., Liu, S., Li, J., Wen, Y., Yang, C., Sun, S. Y., Lu, H., Zhang, Y., et al. (2026) · Advanced Materials · doi:10.1002/adma.73362 · Cited by 4
Exploring the role of cationic lipids in modulating immunogenicity and vaccine efficacy of mRNA-LNP
Zhou, Y., Shan, X., Gu, R., Xia, Y., & Huang, X. (2024) · Particuology · doi:10.1016/j.partic.2024.11.011 · Cited by 4
Chen, X., Zhang, H., Liu, D., Ma, J., Jin, L., Ma, Y., Li, J., Song, G., & Wang, J. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00117j · Cited by 4
Nanocoding: Lipid Nanoparticle Barcoding for Multiplexed Single-Cell RNA Sequencing
Feng, Y., Chen, D., Applegate, C. C., Medina, N. G., Kuo, C.-W., Arogundade, O. H., Wright, C. L., Xu, F., Drnevich, J. M., & Smith, A. M. (2025) · ACS Nano · doi:10.1021/acsnano.5c02111 · Cited by 4
Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development
Cholkar, S. S., Gawade, A. R., & Kuchekar, A. B. (2022) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2979 · Cited by 4
Ongun, M., Lokras, A. G., Foged, C., & Thakur, A. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_11 · Cited by 4
Hildt, E. (2022) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-022-03600-4 · Cited by 4
Hashimoto, M., Yonezawa, S., Song, F., Nitta, C., Maeda, N., Tomita, K., Yokouchi, A., Koide, H., & Asai, T. (2023) · Biomaterials Science · doi:10.1039/d3bm00068k · Cited by 4
Liposomes: from August Wassermann to Vaccines Against COVID-19
Grygorieva, G., Pylypenko, D., & Krasnopolsky, Y. (2023) · ADMET & DMPK · doi:10.5599/admet.1926 · Cited by 4
Almeida, B., Dias, T. R., Teixeira, A. L., Dias, F., & Medeiros, R. (2023) · Cancers · doi:10.3390/cancers15164017 · Cited by 4
The Use of Medicinal Plant Extract in Hand Sanitizer and Spray to Combat Against Covid-19
Cholkar, S. S., Gawade, A. R., & Kuchekar, A. B. (2022) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2977 · Cited by 4
Improving mRNA vaccine safety and efficiency with cationized lipid nanoparticle formulaPreprint
Xu, P., Liao, G., Ren, D., Zhou, Y., Wu, X., Lei, Y., Zhang, Y., Chen, L., He, C., Zhang, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.29.534838 · Cited by 4
Constant-pH MD Simulations of LipidsPreprint
Trollmann, M. F. W., Rossetti, P., & Böckmann, R. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.06.627182 · Cited by 4
Zeolitic imidazolate frameworks enhanced transfection efficiency of mRNA loaded lipid nanoparticles
Singh, R., Bruce, K., Heazlewood, S. Y., White, J. F., de Vries, M., Muir, B. W., Cao, B., Mulet, X., Layton, D., & Doherty, C. M. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02101k · Cited by 3
Huang, H., Xuan, Y., & Ma, Z.-C. (2025) · Nanotechnology Science and Applications · doi:10.2147/nsa.s500407 · Cited by 3
Francis, J. A., Wright, L., Oerlemans, S. K., van Wegen, R., & Falconer, R. J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126196 · Cited by 3
Toroidal mixers for microfluidic assembly of therapeutic lipid nanoparticles (LNPs): a review
Choi, J., Jeong, H., Jung, S. Y., & Kim, S. (2025) · Korea-Australia Rheology Journal · doi:10.1007/s13367-025-00138-0 · Cited by 3
mRNA Vaccines for Cancer Treatment
Torphy, R. J., Balachandran, V., & Soares, K. C. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.006 · Cited by 3
Johansson, L., Raggi, G., Cartwright, J., Lindqvist, J., Froment, L., Andersson, P., Betts, C. J., Hornberg, J. J., Hobi, N., Ollerstam, A., et al. (2026) · Archives of Toxicology · doi:10.1007/s00204-025-04269-9 · Cited by 3
Mukalel, A. J., Tylek, T., Geisler, H. C., O’Brien, E. M., Frazee, C. P., Li, J. J., Thatte, A. S., Safford, H. C., Figueroa‐Espada, C. G., Alameh, M., et al. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70138 · Cited by 3
Labonia, M. C. I., de Castilla, P. E. M., van der Kraak, P. H., Brans, M. A. D., Yang, Q., Lei, Z., de Jager, S. C. A., de Voogt, W. S., Schiffelers, R. M., Sluijter, J. P. G., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102939 · Cited by 3
Akkineni, S., Gulani, M. A., Kouzi, S. A., D’Souza, M. J., & Uddin, M. N. (2026) · Pharmaceuticals · doi:10.3390/ph19050663 · Cited by 5
He, Y., Wang, L., Velayutham, R., Valerio, T. I., Ricketts, S. D., Sun, Y., Annan, A. C., Bowman, J., Tran, T. S., Mohammadnejad, M., et al. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c05213 · Cited by 3
Mo, Y., & Zheng, G. (2026) · ACS Nano · doi:10.1021/acsnano.6c09354 · Cited by 3
Walters, A. A., Hanafy, B. I., Lu, C., Marelli, S., Zam, A., Liu, K., Foreman, R. E., Soundararajan, R., Collin, P., Lindfors, L., et al. (2026) · Small · doi:10.1002/smll.74283 · Cited by 3
Lawton, S., Manson, M. A., Fan, M., Chao, T.-Y., Chen, C., Kim, P., Campbell, C., Cai, X., Kooi, A. V., & Miao, C. H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.010 · Cited by 3
Chiu, C.-T., Tsai, H., Chen, J.-Y., Hu, C. J., & Chen, H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s463546 · Cited by 3
Nanomaterials as a Versatile Tool for COVID-19 Treatment
Zeinali, S., Moafian, Z., Arshad, R., Karimi, F., Zeinalilathori, S., Rahdar, A., Fathi‐karkan, S., & Pandey, S. (2024) · BioNanoScience · doi:10.1007/s12668-024-01538-2 · Cited by 3
Improving the Efficacy of Cancer mRNA Vaccines
Kirtane, A. R., & Traverso, G. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000764 · Cited by 3
Park, S.-H., Kim, Y., Kim, M.-A., Lee, Y. J., Seo, Y., Jin, H., & Lee, S. (2025) · Applied Sciences · doi:10.3390/app15084428 · Cited by 3
Lipid Nanoparticles for Driving Macrophages to Promote Proinflammatory Cytokine Upregulation
Manturthi, S., Courtemanche, A., Zaidi, Z., Patwari, A., Graham, L., Wang, L., Iqbal, U. H., Nguyen, T. H., Côté, M., & Gadde, S. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c06802 · Cited by 3
Forster, J., Fish, A., Malhotra, M., Pinjari, A., Debnath, M., & Kulkarni, A. A. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503771 · Cited by 3
Billing, L., Martin, L., Henser‐Brownhill, T., Samangouei, P., Leach, A., Knight, P., Apostolidou, M., Ladak, A., Nagel, B., & Kwok, A. (2025) · Advanced Science · doi:10.1002/advs.202514417 · Cited by 3
Research progress in mRNA drug modification and delivery systems
Zhou, Z., & Li, X. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0101 · Cited by 4
Shah, N. N., Dave, B. P., Shah, K. C., Shah, D. D., Maheshwari, K. G., Chorawala, M. R., Parekh, P. S., & Jani, M. A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03037-3 · Cited by 3
RetractedLin, G.-B., Shih, C., Liutkevičienė, R., Rovīte, V., So, E. C., Wu, C., & Wu, S. (2024) · Biophysica · doi:10.3390/biophysica4020009 · Cited by 3
Matayoshi, K., Song, F., Koide, H., Yonezawa, S., Nitta, C., Okada, M., Ozaki, N., Kurata, M., & Asai, T. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150372 · Cited by 3
Liposomal Technology in Drug Formulations: Enhancing Therapeutic Efficacy and Safety
Patel, V., & Dave, P. Y. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1007868 · Cited by 3
Enhanced‐mRNA Delivery Using Ultrasound‐Delivered Anchors for Bioorthogonal Ligation
Ianni, E. D., Jeon, J., Mohammadi, S., Hu, H., Quintana, J. M., Lee, C., Haidar, E. A., Goemans, M., Zargani‐Piccardi, A., Mahamdeh, M., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.202523437 · Cited by 3
Coronavirus disease 2019 vaccines: perspectives and update
Kaushik, S. K., Bobdey, S., Faujdar, D. S., Anand, V. R., & Yadav, A. K. (2021) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2021.04.003 · Cited by 3
COVID-19 and the Unraveling of Experimental Medicine - Part II
Thorp, K. E., & Thorp, J. A. (2022) · The Gazette of Medical Sciences · doi:10.46766/thegms.pubheal.22022804 · Cited by 3
Pan, Y., Jin, L., Huang, Y., Jian, D., Васильевич, К. И., Beluga, M., STALYBKA, A. S., Mou, X., Zhu, Y., Mao, Z., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202424205 · Cited by 2
Engineered and Artificial Exosomes for Non-viral Drug Delivery Nanocarriers
Maeki, M., & Tokeshi, M. (2025) · Springer eBooks · doi:10.1007/978-981-97-7067-0_19 · Cited by 2
Kim, J., Yang, J., Heo, S., & Poo, H. R. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00424 · Cited by 2
Potent Cross‐neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein
Ren, Y., Fan, P., Zhang, X., Fang, T., Chen, Z., Yao, Y., Chi, X., Zhang, G., Zhao, X., Sun, B., et al. (2025) · Advanced Science · doi:10.1002/advs.202501996 · Cited by 2
Meulewaeter, S., Velder, M. D., Reckelbus, D., Mwangi, K., Ehouarne, T., Aernout, I., Engelen, Y., Halimi, F., herteryck, I. V., Bels, L. D., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101493 · Cited by 3
Modeling transitional fouling mechanisms for mRNA-lipid nanoparticles during sterile filtration
Messerian, K. O., Zverev, A., Kramarczyk, J. F., & Zydney, A. L. (2025) · Journal of Membrane Science · doi:10.1016/j.memsci.2025.124278 · Cited by 2
Zhi, Z., Liu, T., Kang, J., Zhou, F.-C., Liu, X., & He, Z. (2025) · World Journal of Orthopedics · doi:10.5312/wjo.v16.i7.107045 · Cited by 2
A naturally derived lipopeptide lipid nanoparticle platform enabling multiple nucleic acids delivery
Han, X., Feng, B., Gao, D., Shi, S., Yang, Y., Zhang, Y., Wang, F., Yao, Q., Song, H., Liu, Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.09.007 · Cited by 3
Metadata
- Authors
- Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M. J., Senn, J. J., Stanton, M. G., Almarsson, Ö., Ciaramella, G., & Brito, L. A.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Brito, Luis A.
- ORCID
- Venue
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 15
- Pages
- 1-11
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC6383180
- OpenAlex
- W2914060533
- Cited by
- 927
- References
- 35
- Citations by year
- 2026: 141 · 2025: 202 · 2024: 162 · 2023: 140 · 2022: 128 · 2021: 114 · 2020: 35 · 2019: 5
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moderna Therapeutics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, intramuscular administration, ionizable lipids, biodegradable lipids, immunogenicity, tolerability, innate immune activation, non-human primates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
